KR900701836A - Peptides useful for diagnosing, preventing or treating new HIV proteins and AIDS - Google Patents

Abstract

No content

Description

Peptides useful for diagnosing, preventing or treating new HIV proteins and AIDS

Since this is an open matter, no full text was included.

1 shows the common occurrence of phosphorus at major neutralization degree. 2 is a schematic of the multi-epitope gene structure. Figure 3 describes the steps for the construction of specific multi-epitope genes.

Claims (101)

(a) major neutralizing domains of HIV variants: (b) some of said major neutralizing domains of HIV variants: or (C) having an amino acid sequence that is equivalent to one of the major neutralizing domains or portions thereof, inducing neutralizing antibodies and / Or a compound capable of binding to it. A naturally occurring HIV envelope protein thereof, comprising the major neutralizing domain of HIV variants or fragments thereof, and having the ability to release and / or bind neutralizing antibodies. The compound of claim 2, wherein the compound is one or more of cysteine, another moiety or protein capable of enhancing immunogenicity, a peptide from a major HIV neutralizing domain, a peptide capable of stimulating T-cells, or a general immune stimulant. A compound which is modified by adding. A compound consisting of amino acids located between positions 296 and 331 of the envelope protein of the HIV variant or between cysteine residues occurring therein, the ability to excrete and / or bind neutralizing antibodies. A compound represented by the following formula and capable of releasing and / or binding HIV neutralizing antibodies: a x G z G y b Wherein X is 13 amino acids long in O: y is 17 amino acids long in O; Z is P, A, S, Q or L: but not both but a or b may be omitted Either a or b includes cysteine, a protein or other moiety capable of improving immunogenicity, a peptide from the major HIV neutralizing domain, a peptide capable of stimulating T-cells or a general immune stimulant. ) The compound of claim 5, wherein the compound is circularized. The compound of claim 5, wherein the compound comprises epitopes obtained from the major neutralizing domain of one or more HIV variants. Polypeptides and their chemical variants selected from the group consisting of: (1) HIV 10Kd fusion protein shown by Sub 1: HIV protein portion of (2) Sub 1: (3 ) HIV labeled Sub 2 18Kd fusion protein: (4) HIV protein portion of Sub 2: (5) as PB1 _RF Indicated HIV 27Kd fusion protein; (6) HIV protein portion of PB1 _RF : (7) HIV 28Kd fusion protein denoted as PB1 _MN : (8) HIV protein portion of PB1 _MN : (9) HIV 26Kd fusion protein denoted as PB1 _SC : (1O) of PB1 _SC . A portion of HIV protein; (11) HIV26Kd fusion protein designated PB1 _WMJ2 : (12) HIV protein portion of PB1 _WMJ2 : (13) Peptide IIIB (BH 10) -PND: (14) Peptide RF-PND: (15) Peptide MN-PND: ( 16) peptide SC-PND: (17) peptide WMJ-2-PND: (18) peptide LAV-MAL-PND; (19) peptide SF-2-PND: (2O) peptide NY5-PND; (21) peptide Z3-PND: (22) peptide WMJ1-PND; (23) Peptide WMJ3-PND: (24) Peptide Z6-PND: (25) Peptide LAVELl-PND: (26) Peptide CDC 451-PND: (27) Peptide CDC 42-PND: (28) Peptide BAL-PND: (29) peptide HIV-2-PND: (30) peptide 135: (31) peptide 136: (32) peptide 139: (33) peptide 141: (34) peptide 6 142: (35) peptide 143: (36) Peptide 131: (37) Peptide l32: (38) Peptide 134: (39) Peptide 339: (4O) RP342 (WMJ2): (41) RP343 (SC): (42) RP (III _B ): (43) RP335 (III _B ): (44) RP337 (III _B ): (45) RP77 (III _B ); (46) RP83 (III _B ): (47) RP79 (III _B ): (48) RP57: (49) RP55: (50) RP75: (5l) RP56: (52) RP59: (53) RP73 (III _B , RF); (54) RP74 (III _B , RF, MN, SC): (55) RP80 (III _B , RF); (56) RP81 (III _B , WMJ1, MN): (57) RP82 (WMJ1, MN); (58) RP137 (III _B , RF): (59) RP140 (III _B , RF): (60) peptide 64 (HIV-IIIB / HIV-MN / HIV-SC): (61) peptide 338 (HIV-III _B / HIV-RF): (62) Peptide l38: (63) RP342: (64) RP96: (65) RP97: (66) RP98: (67) RP99: (68) RP100: (69) RP102: (70 ) RP88: (71) RP91: (72) RP104: (73) RP10: (74) RP108: (75) RP70; (76) RP84: (77) RP144: (78) RP145: (79) RP146: (8O) RP147: (81) RP150: (82) RP151: (83) RP63: (84) RP41: (85) RP61: (86) RP75: (87) RP111: (88) RP113: (89) RP114: (9O) RP116: (91) RP120: (92) RP121c: (93) RP122c: (94) RP123c: A DNA sequence encoding a polypeptide other than a naturally occurring HIV envelope protein comprising the major neutralizing domains of HIV variants or fragments thereof and having the ability to excrete and / or bind neutralizing antibodies. The DNA sequence of claim 9, wherein the polypeptide is represented by the following formula. a x G z G y b Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but either a or b may be omitted: Each of a or b individually comprises cysteine, a protein or other moiety capable of enhancing immunogenicity, a peptide from the major HIV neutralizing domain, a peptide capable of stimulating T-cells or a general immune stimulant. ) A composition comprising at least one compound represented by the following formula, wherein the composition is capable of releasing and / or binding to neutralizing antibodies against various HIV variants. Wherein x is 0-13 amino acids long; y is 0-17 amino acids long; z is P, A, S, Q or L; but not both but a or b may be deleted Each of a or b comprises either cysteine, a protein or other moiety capable of enhancing immunogenicity, a peptide from the major HIV neutralizing domain, a peptide capable of stimulating T-cells or a general immune stimulant. ) The composition of claim 11, wherein x is selected from the following, Z is P, L, A, S or Q and y is selected from the following. x (0) ≡x does not exist x (1) ≡x ₁ x (2) ≡x ₂ x ₁ x (3) ≡x ₃ x ₂ x ₁ x (4) ≡x ₄ x ₃ x ₂ x ₁ x (5) ≡x ₅ x ₄ x ₃ x ₂ x ₁ x (6) ≡x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (7) ≡x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (8) ≡x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (9) ≡x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (10) ≡x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x | ₃ x ₂ x ₁ x (11) ≡x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x | ₄ x ₃ x ₂ x ₁ x (12) ≡x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x | ₅ x ₄ x ₃ x ₂ x ₁ x (13) ≡x ₁₃ x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x | ₆ x ₅ x ₄ x ₃ x ₂ x ₁ y (0) ≡y does not exist y (1) ≡y ₁ y (2) ≡y ₁ y ₂ y (3) ≡y ₁ y ₂ y ₃ y (4) ≡y ₁ y ₂ y ₃ y ₄ y (5) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y (6) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y (7) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y (8) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y (9) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y ₉ y (10) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y (11) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y (12) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y (13) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y (14) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y (15) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y (16) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y (17) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y ₁₇ And wherein x ₁ is I, R, M, IQR, V, L, K, F, S, G, Y, SRG, or Y0R: x ₂ is H, R, Y, T, S, P, F, N, A, K, G, or V; x ₃ is I, L, M, T, V, E, G, F, or Y; x ₄ is R, S, G, H, A, K, or does not exist: x ₅ is K, R, I, N, Q, A, IR, RQ, or does not exist: x ₆ is R, K, S , I, P, QE, G, or T; X ₇ is T, K, V, I, A, R, P, or E; x ₈ is N, NV, Y, KI, I, T, DK, H. or K; x ₉ is N, S, K, E, Y, D, I, or Q; x ₁₀ is N, Y, S, D, G, or H: x ₁₁ is P; x ₁₂ is R, I, or K; x ₁₃ is T, I, M or A: y ₁ is R, K, Q, G, S, or T: y ₂ is A, V, N, R, K, T, S, F. P, or W y ₃ is F, I, V, L, W, Y, G, S, or T: y ₄ is Y, V, H, L, F, S, I, T, M, R, VH, or FT ; y ₅ is T, A, V, Q, H, I, S, Y, or absent; y ₆ is T, R, I, Q, A. M, or does not exist, and Y ₇ is G, E, K, R, T, D, Q, A, H, N, P, or does not exist: y ₈ Is R, Q, E, K, D, N, A, G, S, I, or is absent; Y ₉ is I, V, R, N, G, or absent; y ₁₀ is I, T, V, K, M, R, L, S, E, Q, A. or absent; y ₁₁ is G, R, E, K, H, or absent: y ₁₂ is D, N, I, R, T, S, or absent; y ₁₃ is I, M, ME, L, or absent; y ₁₄ is R, G, K, S, E, or absent: y ₁₅ is Q, K or R: y ₁₆ is A; And y ₁₇ is H, Y, R or Q. The compound of claim 12, wherein x ₁ is I; z is p: y ₁ is R; And y ₂ is A. The composition of claim 12, wherein x ₁ is I: x ₃ is I: Z is P: and y ₁ is R. The composition of claim 12, wherein z is P: y ₁ is R: y ₂ is A: and y ₃ is F. The compound of claim 12, wherein x ₁ is I: x ₂ is H; x ₃ is I; x ₄ is R: x ₅ is K: x ₆ is R; x ₇ is T: z is P: y ₁ is R: y ₂ is A; y ₃ is F; y ₄ is Y: y ₅ is T: y ₆ is T and y ₇ is G. The composition of claim 11 wherein said compound is circularized. The composition of claim 11, wherein a and / or b comprise a peptide from an HIV major neutralizing domain. The method of claim 11, wherein the portion capable of improving immunogenicity is a virus particles, microorganisms or their immunogenic composition. Appropriate animals such as mice, rats, horses, goats, humans or chimpanzees contain the major neutralizing domains or segments of HIV variants, have the ability to excrete and / or bind neutralizing antibodies, and are not naturally occurring HIV envelope proteins. A composition for prevention or treatment comprising immunoglobulins, monoclonal antibodies and / or polyclonal antibodies generated by immunization with a hybrid compound comprising a polypeptide. (a) a mixture of compounds that are not naturally occurring HIV envelope proteins and have the ability to excrete and / or bind neutralizing antibodies and comprise the major neutralizing domains or segments thereof of the variants; Or (b) using a hybrid compound that is not a naturally occurring HIV envelope protein and has the ability to excrete and / or bind to neutralizing antibodies and comprises a polypeptide comprising a major neutralizing domain of the HIV variant or a segment of the two By immunizing the animal or human by using a composition for the prevention or treatment comprising an antibody generated by immunizing the human body or animal with at least a species of compound comprising a major neutralizing domain of the HIV variant. It is not a naturally occurring HIV envelope protein and has the ability to excrete and / or bind to neutralizing antibodies and comprises antibodies raised against a mixture of compounds comprising the major neutralizing domains or segments thereof of HIV variants. Prophylactic or therapeutic composition. A prophylactic or therapeutic composition comprising an antibody directed against at least one compound represented by the following formula and capable of releasing and / or binding an HIV neutralizing antibody. a x G z G y b (Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b can be deleted) Each of a or b comprises either cysteine, a protein or other moiety capable of enhancing immunogenicity, a peptide from the major HIV neutralizing domain, a peptide capable of stimulating T-cells, or a general immune stimulant. ) The composition of claim 23, wherein a and / or b comprise a peptide from the HIV major neutralizing domain. Antibodies Induced Against a Compound Represented by Formula a x G z G y b (Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b can be deleted) Each of a or b comprises either cysteine, a protein or other moiety capable of enhancing immunogenicity, a peptide from the major HIV neutralizing domain, a peptide capable of stimulating T-cells, or a general immune stimulant. ) The antibody of claim 25, wherein x is selected from the following, z is P, L, A, S or Q and y is selected from the following. x (0) ≡x does not exist x (1) ≡x ₁ x (2) ≡x ₂ x ₁ x (3) ≡x ₃ x ₂ x ₁ x (4) ≡x ₄ x ₃ x ₂ x ₁ x (5) ≡x ₅ x ₄ x ₃ x ₂ x ₁ x (6) ≡x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (7) ≡x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (8) ≡x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (9) ≡x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (10) ≡x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x | ₃ x ₂ x ₁ x (11) ≡x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x | ₄ x ₃ x ₂ x ₁ x (12) ≡x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x | ₅ x ₄ x ₃ x ₂ x ₁ x (13) ≡x ₁₃ x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x | ₆ x ₅ x ₄ x ₃ x ₂ x ₁ y (0) ≡y does not exist y (1) ≡y ₁ y (2) ≡y ₁ y ₂ y (3) ≡y ₁ y ₂ y ₃ y (4) ≡y ₁ y ₂ y ₃ y ₄ y (5) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y (6) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y (7) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y (8) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y (9) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y ₉ y (10) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y (11) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y (12) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y (13) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y (14) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y (15) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y (16) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y (17) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y ₁₇ And wherein x ₁ is I, R, M, IQR, V, L, K, F, S, G, Y, SRG, or Y0R: x ₂ is H, R, Y, T, S, P, F, N, A, K, G, or V; x ₃ is I, L, M, T, V, E, G, F, or Y; x ₄ is R, S, G, H, A, K, or not present: x ₅ is K, R, I, N, Q, A, IR, RQ, or not present: x ₆ is R, K, S , I, P, QE, G, or T; x ₇ is T, K, V, I, A, R, P, or E; x ₈ is N, NV, Y, KI, I, T, DK, H. or K; x ₉ is N, S, K, E, Y, D, I, or Q; x ₁₀ is N, Y, S, D, G, or H: x ₁₁ is P; x ₁₂ is R, I, or K; X ₁₃ is T, I, M or A: y ₁ is R, K, Q, G, S, or T: y ₂ is A, V, N, R, K, T, S, F, P, or W y ₃ is F, I, V, L, W, Y, G, S, or T: y ₄ is Y, V, H, L, F, S, I, T, M, R, VH, or FT ; y ₅ is T, A, V, Q, H, I, S, Y, or absent; y ₆ is T, R, I, Q, A. M, or not present, Y ₇ is G, E, K, R, T, D, Q, A, H, N, P, or present: y ₈ Is R, Q, E, K, D, N, A, G, S, I, or absent; y ₉ is I, V, R, N, G, or absent; y ₁₀ is I, T, V, K, M, R, L, S, E, Q, A, or absent; y ₁₁ is G, R, E, K, H, or not present: y ₁₂ is D, N, I, R, T, S, or not present; y ₁₃ is I, M, ME, L, or absent; y ₁₄ is R, G, K, S, E, or absent: y ₁₅ is Q, K or R: y ₁₆ is A; And y ₁₇ is H, Y, R or Q. The antibody of claim 26, wherein the compound is selected from the group consisting of: (a) a-Y-S-N-V-R-N-R-l-H-I-G-P-G-R-A-F-H-T-T-K-R-I-T-b; (b) a-N-N-N-T-S-R-G-I-R-I-G-P-G-R-A-1-L-A-T-E-R-I-I-b: (C) a-N-N-N-T-R-K-G-I-F-I-G-P-G-R-N-I-Y-T-T-G-N-I-I-b; (d) a-N-T-R-K-S-l-R-l-Q-R-G-P-G-R-A-F-V-T-l-G-K-I-G-b; (e) a-N-N-N-T-R-K-R (I or Y) -T-M-G-P-G-R-V- (Y or W) -Y- (X or T)-(A or T) -G-Q-I-I-b: (f) A-N-N-N- (I or T) -R-K- (R or S) -I-T- (R or K) -G-P-G- (R or K) -V-I-Y-A-T-G-Q-l-I-b: (g) a-N-N-N-T-R-K-G-I-Y-V-G-S-G-R- (A or K) -V-T-T-R- (D or H or Q) -K-I- (I or M) -b; (h) a-T-R-Q- (R or S) -T-P-I-G-L-G-Q- (A or S) -L-Y-T-T-R-b: Widely neutralizing immune response, not a naturally occurring HIV envelope protein, capable of releasing and / or binding to neutralizing antibodies, comprising a mixture of compounds comprising the major neutralizing domains of HIV variants or fragments thereof Vaccine composition for generating. It is not a naturally occurring HIV envelope protein and has the ability to release and / or bind neutralizing antibodies, and includes hybrid compounds consisting of polypeptides comprising the major neutralizing domains or segments of HIV variants, and broadly neutralizing immunity. Vaccine composition for generating a reaction. A vaccine composition comprising at least one compound represented by the following formula and capable of releasing and / or binding HIV neutralizing antibodies. a x G z G y b (Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b can be deleted) Each of a or b comprises either cysteine, a protein or other moiety capable of enhancing immunogenicity, a peptide from the major HIV neutralizing domain, a peptide capable of stimulating T-cells, or a general immune stimulant. ) The vaccine composition of claim 30, wherein the composition is formulated with an immunological adjuvant. The vaccine of claim 30, wherein x is selected from the following: z is P, L, A, S or Q and y is selected from the following. x (0) ≡x does not exist x (1) ≡x ₁ x (2) ≡x ₂ x ₁ x (3) ≡x ₃ x ₂ x ₁ x (4) ≡x ₄ x ₃ x ₂ x ₁ x (5) ≡x ₅ x ₄ x ₃ x ₂ x ₁ x (6) ≡x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (7) ≡x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (8) ≡x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (9) ≡x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (10) ≡x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x | ₃ x ₂ x ₁ x (11) ≡x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x | ₄ x ₃ x ₂ x ₁ x (12) ≡x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x | ₅ x ₄ x ₃ x ₂ x ₁ x (13) ≡x ₁₃ x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x | ₆ x ₅ x ₄ x ₃ x ₂ x ₁ y (0) ≡y does not exist y (1) ≡y ₁ y (2) ≡y ₁ y ₂ y (3) ≡y ₁ y ₂ y ₃ y (4) ≡y ₁ y ₂ y ₃ y ₄ y (5) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y (6) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y (7) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y (8) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y (9) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y ₉ y (10) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y (11) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y (12) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y (13) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y (14) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y (15) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y (16) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y (17) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y ₁₇ And wherein x ₁ is I, R, M, IQR, V, L, K, F, S, G, Y, SRG, or Y0R: x ₂ is H, R, Y, T, S, P, F, N, A, K, G, or V; x ₃ is I, L, M, T, V, E, G, F, or Y; x ₄ is R, S, G, H, A, K, or not present: x ₅ is K, R, I, N, Q, A, IR, RQ, or not present: x ₆ is R, K, S , I, P, QE, G, or T; x ₇ is T, K, V, I, A, R, P, or E; x ₈ is N, NV, Y, KI, I, T, DK, H. or K; x ₉ is N, S, K, E, Y, D, I, or Q; x ₁₀ is N, Y, S, D, G, or H: x ₁₁ is P; x ₁₂ is R, I, or K; X ₁₃ is T, I, M or A: y ₁ is R, K, Q, G, S, or T: y ₂ is A, V, N, R, K, T, S, F, P, or W y ₃ is F, I, V, L, W, Y, G, S, or T: y ₄ is Y, V, H, L, F, S, I, T, M, R, VH, or FT ; y ₅ is T, A, V, Q, H, I, S, Y, or absent; y ₆ is T, R, I, Q, A. M, or not present, Y ₇ is G, E, K, R, T, D, Q, A, H, N, P, or present: y ₈ Is R, Q, E, K, D, N, A, G, S, I, or absent; y ₉ is I, V, R, N, G, or absent; y ₁₀ is I, T, V, K, M, R, L, S, E, Q, A, or absent; y ₁₁ is G, R, E, K, H, or not present: y ₁₂ is D, N, I, R, T, S, or not present; y ₁₃ is I, M, ME, L, or absent; y ₁₄ is R, G, K, S, E, or absent: y ₁₅ is Q, K or R: y ₁₆ is A; And y ₁₇ is H, Y, R or Q. The compound of claim 32, wherein x ₁ is I: x ₂ is H; x ₃ is I; x ₄ is R: x ₅ is K: x ₆ is R; x ₇ is T: z is P: y ₁ is R: y ₂ is A; y ₃ is F; y ₄ is Y: y ₅ is T: y ₆ is T and y ₇ is G. 33. The vaccine of claim 32, wherein said compound is selected from the group consisting of: (a) a-Y-S-N-V-R-N-R-l-H-I-G-P-G-R-A-F-H-T-T-K-R-I-T-b; (b) a-N-N-N-T-S-R-G-I-R-I-G-P-G-R-A-1-L-A-T-E-R-I-I-b: (C) a-N-N-N-T-R-K-G-I-F-I-G-P-G-R-N-I-Y-T-T-G-N-I-I-b; (d) a-N-T-R-K-S-l-R-l-Q-R-G-P-G-R-A-F-V-T-l-G-K-I-G-b; (e) a-N-N-N-T-R-K-R (I or Y) -T-M-G-P-G-R-V- (Y or W) -Y- (X or T)-(A or T) -G-Q-I-I-b: (f) A-N-N-N- (I or T) -R-K- (R or S) -I-T- (R or K) -G-P-G- (R or K) -V-I-Y-A-T-G-Q-l-I-b: (g) a-N-N-N-T-R-K-G-I-Y-V-G-S-G-R- (A or K) -V-T-T-R- (D or H or Q) -K-I- (I or M) -b; (h) a-T-R-Q- (R or S) -T-P-I-G-L-G-Q- (A or S) -L-Y-T-T-R-b: The vaccine composition of claim 32, wherein the compound is capable of releasing an antibody that binds to sequence G-P-G-R-A-F. The vaccine composition of claim 32, wherein the compound is capable of releasing an antibody that binds to sequences I-G-P-G-R-A-F. 33. The vaccine composition of claim 32, wherein said compound is capable of releasing an antibody that binds sequence I-G-P-G-R-A. 33. The vaccine composition of claim 32, wherein said compound is capable of releasing an antibody that binds to sequences I-a-I-G-P-G-R, wherein a is any one of 20 amino acids. 39. The vaccine composition of claim 38 wherein a is H. 33. The vaccine composition of claim 32, wherein said compound is capable of releasing an antibody that binds to sequences I-a-I-G-P-G-R-A, wherein a is any one of 20 amino acids. The vaccine composition of claim 40, wherein a is H. The vaccine composition of claim 32, wherein the compound is capable of releasing an antibody that binds to sequences I-a-I-G-P-G-R-A-F, wherein a is any one of 20 amino acids. 43. The vaccine composition of claim 42, wherein a is H. The vaccine composition of claim 30, wherein the compound is circularized. The vaccine composition of claim 30, wherein the compound comprises an epitope obtained from one or more HIV variants. The compound of claim 32, wherein x ₁ is 1; Z is P; y ₁ is R; And y ₂ is A. The compound of claim 32, wherein x ₁ is I: X ₃ is I: Z is P; And y ₁ is R. The compound of claim 32, wherein Z is P: y ₁ is R: y ₂ is A; And y ₃ is F. 33. The compound of claim 32, wherein x is (5), x is (6), x is (7), x is (8), x is (9), x is (10) and x (11). And y is selected from y (5), y (6), y (7), y (8), y (9), y (10), and y (11). 33. The composition of claim 32, wherein the compound has the following animonic sequence. ax ₁₃ -RPx ₁₀ -x ₉ -x ₈ -x ₇ -x ₆ -x ₅ -x | ₄ -x ₃ -x ₂ -x ₁ -GzGy ₁ -y ₂ -y ₃ -y | ₄ -y ₅ -y ₆ -y ₇ -y ₈ -y ₉ -y ₁₀ -Gy ₁₂ -y ₁₃ -Ay ₁₅ Ay ₁₇ -b. (a) a compound that is not a naturally occurring HIV envelope protein, has the ability to release and / or bind neutralizing antibodies, and comprises a major neutralizing domain of HIV variants or fragments thereof; and (b) an antibody against HIV and the compound. And means for detecting a complex formed in the liver, said kit being used to detect said antibody against said HIV in a biological fluid. The kit of claim 51 wherein said compound is represented by the formula: xGzGy (where x is 0 to 13 amino acids long: y is 0 to 17 amino acids long: z is P, A, S, Q or L). The kit of claim 52 wherein x is selected from the following: z is P, L, A, S or Q and y is selected from the following. x (0) ≡x does not exist x (1) ≡x ₁ x (2) ≡x ₂ x ₁ x (3) ≡x ₃ x ₂ x ₁ x (4) ≡x ₄ x ₃ x ₂ x ₁ x (5) ≡x ₅ x ₄ x ₃ x ₂ x ₁ x (6) ≡x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (7) ≡x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (8) ≡x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (9) ≡x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x ₃ x ₂ x ₁ x (10) ≡x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x ₄ x | ₃ x ₂ x ₁ x (11) ≡x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x ₅ x | ₄ x ₃ x ₂ x ₁ x (12) ≡x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x ₆ x | ₅ x ₄ x ₃ x ₂ x ₁ x (13) ≡x ₁₃ x ₁₂ x ₁₁ x ₁₀ x ₉ x ₈ x ₇ x | ₆ x ₅ x ₄ x ₃ x ₂ x ₁ y (0) ≡y does not exist y (1) ≡y ₁ y (2) ≡y ₁ y ₂ y (3) ≡y ₁ y ₂ y ₃ y (4) ≡y ₁ y ₂ y ₃ y ₄ y (5) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y (6) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y (7) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y (8) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y (9) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y ₈ y ₉ y (10) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y (11) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y (12) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y (13) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y (14) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y (15) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y (16) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y (17) ≡y ₁ y ₂ y ₃ y ₄ y ₅ y ₆ y ₇ y | ₈ y ₉ y ₁₀ y ₁₁ y ₁₂ y ₁₃ y ₁₄ y ₁₅ y ₁₆ y ₁₇ And wherein x ₁ is I, R, M, IQR, V, L, K, F, S, G, Y, SRG, or Y0R: x ₂ is H, R, Y, T, S, P, F, N, A, K, G, or V; x ₃ is I, L, M, T, V, E, G, F, or Y; x ₄ is R, S, G, H, A, K, or not present: x ₅ is K, R, I, N, Q, A, IR, RQ, or not present: x ₆ is R, K, S , I, P, QE, G, or T; x ₇ is T, K, V, I, A, R, P, or E; x ₈ is N, NV, Y, KI, I, T, DK, H. or K; x ₉ is N, S, K, E, Y, D, I, or Q; x ₁₀ is N, Y, S, D, G, or H: x ₁₁ is P; x ₁₂ is R, I, or K; X ₁₃ is T, I, M or A: y ₁ is R, K, Q, G, S, or T: y ₂ is A, V, N, R, K, T, S, F, P, or W y ₃ is F, I, V, L, W, Y, G, S, or T: y ₄ is Y, V, H, L, F, S, I, T, M, R, VH, or FT ; y ₅ is T, A, V, Q, H, I, S, Y, or absent; y ₆ is T, R, I, Q, A. M, or not present, Y ₇ is G, E, K, R, T, D, Q, A, H, N, P, or present: y ₈ Is R, Q, E, K, D, N, A, G, S, I, or absent; y ₉ is I, V, R, N, G, or absent; y ₁₀ is I, T, V, K, M, R, L, S, E, Q, A, or absent; y ₁₁ is G, R, E, K, H, or not present: y ₁₂ is D, N, I, R, T, S, or not present; y ₁₃ is I, M, ME, L, or absent; y ₁₄ is R, G, K, S, E, or absent: y ₁₅ is Q, K or R: y ₁₆ is A; And y ₁₇ is H, Y, R or Q. The vaccine of claim 51, wherein said compound is selected from the group consisting of: (a) a-Y-S-N-V-R-N-R-l-H-I-G-P-G-R-A-F-H-T-T-K-R-I-T-b; (b) a-N-N-N-T-S-R-G-I-R-I-G-P-G-R-A-1-L-A-T-E-R-I-I-b: (C) a-N-N-N-T-R-K-G-I-F-I-G-P-G-R-N-I-Y-T-T-G-N-I-I-b; (d) a-N-T-R-K-S-l-R-l-Q-R-G-P-G-R-A-F-V-T-l-G-K-I-G-b; (e) a-N-N-N-T-R-K-R (I or Y) -T-M-G-P-G-R-V- (Y or W) -Y- (X or T)-(A or T) -G-Q-I-I-b: (f) A-N-N-N- (I or T) -R-K- (R or S) -I-T- (R or K) -G-P-G- (R or K) -V-I-Y-A-T-G-Q-l-I-b: (g) a-N-N-N-T-R-K-G-I-Y-V-G-S-G-R- (A or K) -V-T-T-R- (D or H or Q) -K-I- (I or M) -b; (h) a-T-R-Q- (R or S) -T-P-I-G-L-G-Q- (A or S) -L-Y-T-T-R-b: It is not a naturally occurring HIV envelope protein and has the ability to release and / or bind to neutralizing antibodies and antibodies to HIV in fluids using at least some of the compounds comprising the major neutralizing domains of HIV variants or their fragments. Immunological assays for detecting and / or quantifying The method of claim 55, wherein the compound is represented by the following formula. axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) Widely neutralized, not a naturally occurring HIV envelope protein, capable of releasing and / or binding neutralizing antibodies, and immunizing with a compound composed of compounds comprising the major neutralizing domains or segments of HIV variants Methods of Producing Polyclonal or Monoclonal Antibodies. A wide range of neutralizing polyclonal or monoclonal antibodies that have the ability to excrete and / or bind neutralizing antibodies and consist of immunizing with hybrid compounds comprising polypeptides comprising the major neutralizing domains of HIV variants or fragments thereof Method of creation. (a) a compound that is not a naturally occurring HIV envelope protein and has the ability to excrete and / or bind neutralizing antibodies and consists of compounds comprising the major neutralizing domains or segments of HIV variants; Or (b) using a hybrid compound that is not a naturally occurring HIV envelope protein and has the ability to excrete and / or bind to neutralizing antibodies and comprises a polypeptide comprising a major neutralizing domain of HIV variants or fragments thereof A method of producing a wide range of neutralizing antibodies, comprising a method of immunizing a human or an animal with at least a kind of compound comprising a major neutralizing domain of the HIV variants or by segmenting them by immunizing an animal or a human. 60. The method of claim 59, wherein the method is represented by the following formula and consists of immunization using at least one compound having the capacity to release and / or bind neutralizing antibodies. axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) (a) having the ability to excrete and / or bind to neutralizing antibodies, and to cultivate compounds other than naturally occurring HIV envelope proteins, including important neutralizing domains of HIV variants or fragments thereof, and (b) Detecting an antibody against HIV in a biological fluid consisting of detecting a complex formed between said compound. The method of claim 61, wherein the compound is represented by the formula: xGzGy (Where x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L) A composition comprising an antibody which is not a naturally occurring HIV envelope protein, has the ability to release and / or bind neutralizing antibodies, and which is directed against a mixture of compounds comprising a major neutralizing domain of HIV variants or a segment thereof A method of preventing or treating HIV infection, comprising administering to an animal or human body in need of prevention or treatment. 64. The method of claim 63, wherein the compound is represented by the formula: axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) At least one compound that is not a naturally occurring HIV envelope protein, has the ability to excrete and / or bind neutralizing antibodies, and contains at least a neutral neutralizing domain of HIV variants or fragments thereof, for treating a human body requiring stimulation of a proliferative response Lymphocyte proliferation response stimulation method in the human body consisting of. 66. The method of claim 65, wherein the compound is represented by the formula: axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) A composition that is not a naturally occurring HIV envelope protein, has the ability to release and / or bind neutralizing antibodies, and contains a composition comprising one or more compounds comprising a major neutralizing domain of HIV variants or a segment thereof, requiring treatment for HIV infection An HIV infection treatment method comprising administering to an animal or human body. The method of claim 67, wherein the compound is represented by the formula: axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) (a) is not a naturally occurring HIV envelope protein and has the ability to excrete and / or bind neutralizing antibodies, contacting biological fluids with antibodies specific for compounds comprising the major neutralizing domains or segments of HIV variants; and (b) analyzing said biological fluid for the presence of HIV variant-specific proteins consisting of detecting immunocomplexes by identifying HIV variants in said rapeseed. The method of claim 69, wherein the compound is represented by the formula: axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) It is not a naturally occurring HIV envelope protein, has the ability to release and / or bind neutralizing antibodies, and processes lymphoid cells from immune animals using at least some compound comprising the major neutralizing domains of HIV variants or their fragments. How to stimulate lymphocytes experimentally, consisting of. The method of claim 71, wherein the compound is represented by the formula: axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) Antibody-producing cells by the ability to excrete and / or bind to neutralizing antibodies and to bind at least a type of compound other than naturally occurring HIV envelope proteins, including the major neutralizing domains of HIV variants or their segments A method of identifying polyclonal or monoclonal antibodies useful for the treatment or prophylaxis consisting of screening. The method of claim 73, wherein the compound is represented by the formula: The compound is represented by the following formula. axGzGyb Wherein x is 13 amino acids long in O: y is 17 amino acids long in O; z is P, A, S, Q or L: but not both but a or b may be deleted And each of a or b comprises either cysteine, a protein or other moiety that can enhance immunogenicity, a peptide from a major HIV neutralizing domain, a peptide that can stimulate T-cells, or a general immune stimulant do.) A synthetic gene encoding a polypeptide comprising one or more HIV neutralizing epitopes. A synthetic gene encoding a polypeptide comprising a neutralizing epitope obtained from one or more HIV isolates. The synthetic gene of claim 76, wherein the polypeptide comprises neutralizing epitopes obtained from 2 to 20 HIV isolates. The synthetic gene of claim 76, wherein one of the neutralizing epitopes is obtained from an HIV isolate named HIV-MN. 77. The synthetic gene of claim 76, wherein the polypeptide comprises neutralizing epitopes obtained from HIV isolates designated as HIV-MN, HIV-IIIB, HIV-RF, HIV-SC, and HIV-WMJ1. 77. The synthetic gene of claim 76, wherein the regions encoding neutralizing epitopes obtained from different HIV isolates are separated by amino acid spacers. The synthetic gene of claim 80, wherein the amino acid spacer is glycine. 77. The synthetic gene of claim 76, wherein said gene encodes a polypeptide having an amino acid sequence shown in Table 13 or an equivalent amino acid sequence. 77. The synthetic gene of claim 76, wherein said gene encodes a fusion polypeptide. 84. The synthetic gene according to claim 83, wherein said gene has an amino acid sequence shown in Table 13A or an equivalent amino acid sequence. A compound comprising neutralizing epitopes obtained from one or more HIV isolates. 86. The compound of claim 85, wherein said compound comprises neutralizing epitopes obtained from 2 to 20 HIV isolates. 86. The compound of claim 85, wherein one of the neutralizing epitopes is obtained from an HIV isolate named HIV-MN. 86. The compound of claim 85, wherein the compound comprises neutralizing epitopes obtained from HIV isolates designated HIV-MN, HIV-IIIB, HIV-RF, HIV-SC, and HIV-WMJ1. 86. The compound of claim 85, wherein said neutralizing epitopes are separated by amino acid spacers. 90. The compound of claim 89, wherein said amino acid spacer is glycine. 86. The compound of claim 85, wherein the compound has an amino acid sequence shown in Table 13 or an equivalent amino acid sequence. 86. The compound of claim 85, wherein said compound is a fusion polypeptide. 93. The compound of claim 92, wherein the compound has an amino acid sequence shown in Table 13A or an equivalent amino acid sequence. One of the isolates is an immunoglobulin, monoclonal antibody and / or generated by immunizing an appropriate animal with a composition consisting of a multi-epitope compound comprising neutralizing epitopes obtained from 2 to 20 HIV isolates that are HIV-MN. Prophylactic or therapeutic composition comprising a polyclonal antibody. 95. The composition of claim 94, wherein said multi-epitope compound comprises neutralizing epitopes obtained from HIV isolates designated as HW-MN, HIV-IIIB, HIV-RF, HIV-SC, and HIV-WMJ1. A broad range of polyclonal or monoclonal antibodies composed of immunizing a suitable animal with a composition comprising a multi-epitope compound comprising neutralizing epitopes obtained from 2 to 20 HIV isolates, wherein one of the isolates is HIV-MN How to generate. 97. The method of claim 96, wherein the multi-epitope compound comprises neutralizing epitopes obtained from HIV isolates ordered HW-MN, HIV-IIIB, HIV-RF, HIV-SC, and HIV-WMJ1. Way. One of the isolates is a composition comprising a multi-epitope compound comprising neutralizing epitopes obtained from 20 to 20 HIV isolates that are HIV-MN and immunoglobulins, monoclonal antibodies and / or generated by immunizing a suitable animal. Or administering a pharmaceutical composition comprising a polyclonal antibody to an animal or human body in need of prevention or treatment of HIV. 99. The method of claim 98, wherein said multi-epitope compound comprises neutralizing domains obtained from HIV isolates designated as HW-MN, HIV-IIIB, HIV-RF, HIV-SC, and HIV-WMJ1. One of the isolates is a composition comprising a plurality of epitope compounds comprising neutralizing domains derived from 2 to 20 HIV isolates, HIV-MN, lymphocytes in the human body consisting of treating the human body in need of stimulation of a lymphocyte proliferation response. How to stimulate proliferative response. 101. The method of claim 100, wherein said multi-epitope compound comprises neutralizing epitopes obtained from HIV isolates directed to HIV-MN, HIV-IIIB, HIV-RF, HIV-SC, and HIV-WMJ1. ※ Note: The disclosure is based on the initial application.